T-cell lymphoma (TCL) originates from mature T cells and natural killer cells and is a rare malignant lymphatic and hematopoietic tumor that accounts for 12% of all lymphomas[@b1]. In China, TCL accounts for 34% of non-Hodgkin\'s lymphomas (NHLs), and the incidence of TCL is increasing[@b2]--[@b4]. The prognosis of TCL is inferior to that of B-cell lymphoma. Currently, the international prognostic index (IPI) is widely used to predict the prognosis of TCL. IPI is determined by multiple factors, including patient age, performance status, serum lactic dehydrogenase level, tumor stage, extranodal and bone marrow involvement. However, IPI is not applicable for predicting the prognosis of all patients, suggesting that other factors may also play roles in patient prognosis. A substantial amount of recent investigations indicated that genetic variations exert significant effects on the prognosis of cancer patients. However, the exact genetic variations remain to be identified.

Tumor necrosis factor (TNF) refers to a group of cytokines secreted by lymphocytes and macrophages. TNF has multiple functions, such as inflammatory response, immune regulation, and antitumor effects. The biological functions of TNF are mediated by TNF receptor superfamily (TNFSF), which possesses similar structures and functions. Previous studies revealed that single nucleotide polymorphisms (SNPs) in the *TNF-α* promoter are associated with increased risk of NHL[@b5],[@b6], indicating that they might also affect the progress of TCL. Nevertheless, TCL pathogenesis is complex, and few studies focusing on the association between genetic factors and prognosis have been performed. Currently, no studies have been conducted to analyze the relationship between *TNFRSF* genetic variations and the survival of TCL patients. In this study, we investigated the associations between multiple SNPs in 18 *TNFRSF* genes and the survival of patients with TCL.

Subjects and Methods {#s2}
====================

Patients {#s2a}
--------

A total of 150 TCL patients diagnosed at the Cancer Institute & Hospital, Chinese Academy of Medical Sciences between January 1992 and April 2009 were enrolled in this study. The subjects had T-lymphoblastoma or leukemia, anaplastic large cell lymphoma, mycosis fungoides, adult T-cell leukemia or TCL, and peripheral TCL. All patients underwent CHOP regimen (cyclophosphamide, adriamycin, vincristine, and prednisone) or CHOP-based chemotherapy. All patients were Han ethnicity. Patients\' clinical information, including age, sex, tumor classification and stage, and IPI were obtained from medical records. Overall survival was measured from the date of diagnosis to the date of last follow-up or death. Whether and when a patient died were obtained from inpatient and outpatient records, patients\' families, or local Public Security Census Register Office through follow-up telephone calls. This study was approved by the Institutional Review Board of Chinese Academy of Medical Sciences Cancer Institute. Informed consent was signed by all patients.

SNP selection and genotype analysis {#s2b}
-----------------------------------

Genomic DNA was extracted from patient peripheral blood samples or paraffin-embedded lymphoma biopsy samples. Blood DNA kit (catalog number: DP319-02) was provided by Tiangen Biochemical Technology Co., Ltd. (Beijing, China). The Wizard MagneSil genomic DNA purification system (catalog number: MD1490) was provided by Promega Company. The procedure was performed strictly according to the manufacturer\'s instructions.

SNPs within the *TNFRSF* genes[@b7] and their 2-kb upstream and downstream with the minor allele frequency (MAF) ≥0.05 were selected according to the HapMap database of Chinese population (NCBI Build 36). All SNPs on the same chromosome were compared pairwise to measure the linkage disequilibrium, and *r*^2^ \> 0.8 was used to determine the tag SNPs. The tag SNPs located in gene regulatory and/or coding regions were genotyped and relevant association analysis was performed. By using these criteria, 38 SNPs in 18 *TNFRSF* genes were chosen and genotyped using the Sequenom platform by CapitalBio Co. (Beijing, China).

Statistical analysis {#s2c}
--------------------

SAS 9.0 software was used for statistical analyses. Cox regression under a log-additive genetic model was performed for genotypes with adjustment for covariates, including sex and IPI score, that might influence patients\' survival. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were calculated. Kaplan-Meier survival estimates were plotted and *P* values were assessed using log-rank tests. The survival package in R was used to perform the analyses of TCL-related death. All statistical analyses were two- side tests. *P* values \< 0.05 were considered significant.

Results {#s3}
=======

Patient characteristics {#s3a}
-----------------------

The clinical characteristics of the patients are presented in [Table 1](#cjc-31-07-335-t01){ref-type="table"}. Among the 150 patients, 99 were males and 51 were females. Thirty-one patients had precursor TCL and 119 had mature TCL. The numbers of stage I, II, III, and IV patients were 37, 49, 19, and 45, respectively. A total of 149 patients had IPI scores: 38 scored 0; 51 scored 1; 40 scored 2; 16 scored 3; and 4 scored 4. By February 2011, 69 patients (46.0%) died of TCL: 16 had precursor TCL (median survival: 22 months; 5-year survival rate: 18%), and the other 53 had mature TCL (median survival: 48 months; 5-year survival rate: 47.8%).

###### Distribution of basic clinical characteristics of the patients with T-cell lymphoma

  Characteristic                Patients \[cases (%)\]   Deaths \[cases (%)\]   Median survival (months)
  ---------------------------- ------------------------ ---------------------- --------------------------
  Total                                  150                      69           
  Age (years)                                                                  
   ≤60                                135 (90.0)              61 (88.4)                   46.0
   \>60                               15 (10.0)                8 (11.6)                   96.0
  Gender                                                                       
   Male                               99 (66.0)               44 (63.8)                   47.0
   Female                             51 (34.0)               25 (36.2)                   45.0
  Subtype^a^                                                                   
   Precursor T-cell neoplasm          31 (20.7)               16 (23.2)                   22.0
   Mature T-cell neoplasm             119 (79.3)              53 (76.8)                   48.0
  Stage                                                                        
   I                                  37 (24.7)               12 (17.4)                 34.6^b^
   II                                 49 (32.7)               21 (30.5)                   48.0
   III                                19 (12.6)                9 (13.0)                   96.0
   IV                                 45 (30.0)               27 (39.1)                   24.0
  IPI score                                                                    
   0                                  38 (25.3)                8 (11.6)                 41.4^b^
   1                                  51 (34.0)               29 (42.0)                   24.0
   2                                  40 (26.7)               18 (26.1)                   48.0
   3                                  16 (10.7)               11 (15.9)                   12.0
   4                                   4 (2.7)                 3 (4.4)                    21.0
   5                                    0 (NC)                  0 (NC)                     NC
   Unknown                             1 (0.7)                  0 (NC)                     NC

IPI, international prognostic index; NC, not calculated. ^a^Precursor T-cell neoplasm includes precursor T-lymphoblastic lymphoma/leukemia; mature T-cell neoplasm includes peripheral T-cell lymphoma, anaplastic large-cell lymphoma, mycosis fungoides, and adult T-cell leukemia/lymphoma. ^b^Mean survival time is provided because median survival time is not reached.

Effect of SNPs in the *TNFRSF* genes on patient survival {#s3b}
--------------------------------------------------------

In total, 38 tag SNPs in 18 *TNFRSF* genes were genotyped ([Table 2](#cjc-31-07-335-t02){ref-type="table"}). The results of association analysis between these 38 SNPs and the survival of TCL patients are presented in Table 3. Three SNPs (rs3759333C\>T at *LTβR*, rs2017662C\>T at *TNFRSF17*, and rs2071336C\>T at *TNFRSF17*) were associated with the TCL patient survival ([Table 4](#cjc-31-07-335-t04){ref-type="table"}).

###### Tagging SNPs genotyped within selected candidate genes of the tumor necrosis factor receptors and corresponding ligands

  Gene              SNP        Location
  ------------- ------------ ------------
  *TNFRSF1A*     rs4149570     Upstream
                 rs2234649     Upstream
                  rs767455       Exon
  *LTβR*         rs3759333     Upstream
                 rs2364480       Exon
                  rs12354     Downstream
  *TNFRSF7*      rs2286598     Upstream
                 rs2286597     Upstream
                 rs11569361    Upstream
  *TNFRSF8*         None     
  *TNFRSF1B*      rs945439       Exon
                 rs1061622       Exon
                 rs1061624      3′ UTR
                   rs3397       3′ UTR
                 rs1061628      3′ UTR
                 rs1061631      3′ UTR
  *TNFRSF9*       rs519546     Upstream
                  rs161826      3′ UTR
  *TNFRSF12A*     rs13209       3′ UTR
  *TNFRSF13B*    rs11078355      Exon
  *TNFRSF13C*    rs7290134      3′ UTR
  *TNFRSF14*     rs3762440     Upstream
                 rs2234167       Exon
  *TNFRSF17*     rs12926535    Upstream
                 rs2017662       Exon
                 rs2071336       Exon
                 rs1126889      3′ UTR
  *CD40*          rs752118     Upstream
                 rs1883832      3′ UTR
  *TRADD*           None     
  *TNFRSF10B*    rs1047266       Exon
                 rs1047275      3′ UTR
  *TNFRSF10C*    rs12549481    Upstream
  *TNFRSF10D*    rs6651394     Upstream
                 rs1133782       Exon
                   rs7957       3′ UTR
  *TNFRSF10A*    rs13278062    Upstream
  *TNFRSF25*        None     
  *FAS*          rs1468063      3′ UTR
  *FASL*          rs763110     Upstream
  *FADD*            None     
  *CFLAR*          rs1594        Exon

SNP, single nucleotide polymorphism; UTR, untranslated region.

###### Table 3. Genetic variations in tumor necrosis factor receptor and corresponding ligand genes and association with survival of the patients with T-cell lymphomaa

  Gone              SNP       Common homozygote   Heterozygote   Rare homozygote   Dominant model   Recessive model                                                                                                                          
  ------------- ------------ ------------------- -------------- ----------------- ---------------- ----------------- ---- ------------------ ------- ---- ---- ---- ------------------ ------- ------------------ ------- ------------------ -------
  *TNFRSF1A*     rs4149570           TT                39              16                GT               58          27   1.35(0.71-2.57)    0.353   GG   37   18   1.21 (0.58-2.52)   0.620   1.28(0.71-2.32)    0.409   1.04(0.59-1.85)    0.885
                 rs2234649           AA               107              47                CA               18          8    0.89 (0.41-1.90)   0.760   CC   9    4    1.05(0.37-2.95)    0.933   0.95(0.50-1.82)    0.877   1.10 (0.39-3.07)   0.859
                  rs767455           TT                99              45                CT               43          18   0.71 (0.40-1.25)   0.236   CC   3    2    0.98 (0.21-4.47)   0.978   0.72(0.42-1.25)    0.247   1.18 (0.28-5.00)   0.826
  *LTβR*         rs3759333           CC                52              18                TC               56          27   1.40(0.76-2.59)    0.284   TT   27   16   2.46(1.22-4.97)    0.012   1.67(0.95-2.93)    0.072   1.78(1.00-3.17)    0.051
                 rs2364480           AA               107              46                CA               24          14   1.18(0.64-2.19)    0.596   CC   14   7    0.97 (0.43-2.19)   0.947   1.09(0.64-1.86)    0.744   0.95 (0.43-2.10)   0.894
                  rs12354            GG               104              46                TG               23          14   1.22(0.66-2.56)    0.535   TT   9    2    0.39(0.09-1.62)    0.194   0.96(0.53-1.73)    0.893   0.38(0.09-1.56)    0.177
  *TNFRSF7*      rs2286598           CC                36              17                GC               72          34   1.30 (0.72-2.36)   0.379   GG   28   9    0.63(0.26-1.50)    0.292   1.07(0.61-1.90)    0.809   0.56 (0.27-1.20)   0.137
                 rs2286597           CC               108              48                TC               38          18   1.02(0.58-1.78)    0.953   TT   1    0           NC           NC     1.00(0.57-1.74)    0.988          NC           NC
                 rs11569361          GG                63              29                AG               49          24   1.32(0.77-2.27)    0.320   AA   12   2    0.28(0.07-1.18)    0.083   1.04(0.61-1.76)    0.895   0.26(0.06-1.09)    0.066
  *TNFRSF1B*      rs945439           TT                83              34                CT               36          17   1.39(0.77-2.52)    0.277   CC   16   11   1.73(0.81-3.66)    0.154   1.61 (0.96-2.68)   0.072   1.75 (0.86-3.56)   0.123
                 rs1061622           TT                86              35                GT               42          19   1.25(0.71-2.22)    0.437   GG   18   12   1.73(0.86-3.48)    0.123   1.45(0.89-2.38)    0.139   1.67 (0.86-3.22)   0.128
                 rs1061624           GG                37              16                AG               76          37   1.74(0.93-3.27)    0.083   AA   29   12   1.35(0.60-3.03)    0.463   1.67(0.92-3.04)    0.094   1.01 (0.53-1.90)   0.984
                   rs3397            CC                57              21                TC               54          29   1.66(0.91-3.03)    0.096   TT   18   8    1.37(0.59-3.14)    0.463   1.72(0.98-3.02)    0.062   1.12 (0.53-2.37)   0.771
                 rs1061628           CC                77              33                TC               43          21   1.22(0.70-2.13)    0.478   TT   19   9    1.09(0.51-2.32)    0.828   1.18(0.72-1.95)    0.507   1.01 (0.49-2.07)   0.977
                 rs1061631           GG               127              57                AG               22          12   1.70(0.89-3.26)    0.110   AA   0    0           NC           NC     1.70(0.89-3.26)    0.110          NC           NC
  *TNFRSF9*       rs519546           CC                62              31                AC               56          23   0.77 (0.44-1.34)   0.358   AA   23   11   0.92(0.43-1.95)    0.819   0.82(0.49-1.35)    0.434   1.13 (0.58-2.22)   0.722
                  rs161826           GG                35              17                AG               47          23   0.93 (0.49-1.76)   0.818   AA   23   9    0.66(0.25-1.74)    0.403   0.90(0.49-1.67)    0.737   0.73(0.33-1.62)    0.441
  *TNFRSF12A*     rs13209            AA               102              45                GA               25          12   0.90 (0.48-1.72)   0.756   GG   8    4    0.77 (0.23-2.56)   0.672   0.88(0.49-1.60)    0.676   0.75 (0.23-2.47)   0.640
  *TNFRSF13B*    rs11078355          GG               102              45                AG               39          20   1.11 (0.65-1.90)   0.705   AA   8    4    0.97 (0.34-2.82)   0.961   1.11 (0.67-1.85)   0.678   1.03 (0.37-2.89)   0.951
  *TNFRSF13C*    rs7290134           AA                97              46                GA               37          15   0.89 (0.49-1.60)   0.687   GG   8    2    0.57(0.13-2.47)    0.453   0.82(0.47-1.44)    0.491   0.53 (0.13-2.26)   0.391
  *TNFRSF14*     rs3762440           CC                88              41                TC               38          17   1.04(0.59-1.83)    0.903   TT   14   7    0.82 (0.33-2.04)   0.672   1.00(0.59-1.67)    0.984   0.85 (0.35-2.04)   0.711
                 rs2234167           GG               124              57                AG               23          11   1.06(0.55-2.05)    0.867   AA   0    0           NC           NC     1.06(0.55-2.05)    0.867          NC           NC
  *TNFRSF17*     rs12926535          GG                95              48                AG               39          13   0.63 (0.34-1.18)   0.153   AA   5    1    0.33 (0.04-2.46)   0.280   0.60(0.32-1.10)    0.097   0.40 (0.06-2.95)   0.370
                 rs2017662           CC                94              51                TC               41          13   0.56 (0.30-1.05)   0.070   TT   5    1    0.33 (0.04-2.41)   0.271   0.53 (0.29-0.97)   0.039   0.37 (0.05-2.72)   0.331
                 rs2071336           CC               114              56                TC               24          7    0.49 (0.22-1.09)   0.081   TT   3    0           NC           NC     0.45(0.21-1.00)    0.049          NC           NC
                 rs1126889           GG                47              26                CG               55          22   0.62 (0.35-1.09)   0.096   CC   22   10   0.75(0.35-1.60)    0.452   0.64(0.38-1.09)    0.103   0.89(0.44-1.79)    0.744
  *CD40*          rs752118           CC                66              32                TC               59          27   1.02 (0.60-1.72)   0.948   TT   19   7    0.60(0.25-1.44)    0.248   0.88(0.54-1.45)    0.614   0.58 (0.25-1.35)   0.207
                 rs1883832           CC                54              24                TC               54          28   1.09(0.62-1.94)    0.765   TT   24   10   0.93 (0.42-2.06)   0.862   1.11 (0.65-1.91)   0.697   0.85(0.43-1.71)    0.652
  *TNFRSF10B*    rs1047266           CC                66              31                TC               54          24   0.80 (0.46-1.41)   0.446   TT   17   8    0.98 (0.42-2.28)   0.968   0.87(0.52-1.46)    0.589   1.16 (0.54-2.47)   0.703
                 rs1047275           CC                53              25                GC               56          26   0.94 (0.53-1.66)   0.826   GG   25   11   0.68(0.31-1.49)    0.338   0.90(0.53-1.53)    0.691   0.76(0.38-1.52)    0.436
  *TNFRSF10C*    rs12549481          AA                84              34                GA               45          20   1.14(0.64-2.04)    0.652   GG   15   9    1.99(0.94-4.22)    0.073   1.30(0.78-2.18)    0.311   1.85 (0.90-3.79)   0.093
  *TNFRSF10D*    rs6651394           CC                40              24                TC               64          22   0.64 (0.35-1.17)   0.150   TT   29   14   0.75(0.38-1.47)    0.395   0.66(0.39-1.12)    0.123   1.01 (0.54-1.88)   0.976
                 rs1133782           CC               111              50                TC               17          8    1.17(0.55-2.49)    0.679   TT   2    0           NC           NC     1.08(0.51-2.30)    0.842          NC           NC
                   rs7957            TT                46              21                CT               70          29   0.86 (0.48-1.53)   0.606   CC   29   15   0.93(0.47-1.83)    0.837   0.86(0.51-1.47)    0.591   1.14 (0.64-2.06)   0.656
  *TNFRSF10A*    rs13278062          GG                74              39                TG               49          16   0.61 (0.34-1.10)   0.100   TT   16   9    1.02(0.49-2.14)    0.953   0.73(0.44-1.21)    0.219   1.24 (0.61-2.52)   0.562
  *FAS*          rs1468063           GG                30              13                AG               49          24   1.11 (0.52-2.39)   0.784   AA   5    2    0.80(0.15-4.37)    0.800   1.04(0.50-2.16)    0.922   0.96 (0.23-4.11)   0.950
  *FASL*          rs763110           CC                64              32                TC               33          14   1.27(0.26-6.28)    0.769   TT   7    2    1.80(0.42-7.73)    0.429   1.73(0.41-7.27)    0.458   1.52 (0.82-2.80)   0.182
  *CFLAR*          rs1594            TT                51              22                CT               50          20   0.77 (0.41-1.43)   0.404   CC   9    6    1.66(0.60-4.59)    0.329   0.87(0.48-1.57)    0.636   1.77 (0.72-4.33)   0.213

^a^The total number of individuals may not be the same because of genotyping failure. ^b^Adjusted for sex, subtype, and IPI score.

###### Cox regression of overall survival of three genetic variations in tumor necrosis factor receptor genes for T-cell lymphoma patients

  Gene             SNP      Location   Genotype   Patients (*n* = 150)^a^   Death (*n* = 69)^a^   Median survival (months)   Adjusted HR (95% CI)^b^    *P*    Log-rank *P*
  ------------ ----------- ---------- ---------- ------------------------- --------------------- -------------------------- ------------------------- ------- --------------
  *LTβR*        rs3759333   Upstream      CC                52                      18                      81.0                      1.00                    
                                          TC                56                      27                      28.0                1.40 (0.76 2.59)       0.284      0.102
                                          TT                27                      16                      20.0                2.46 (1.22 4.97)       0.012      0.007
  *TNFRSF17*    rs2017662     Exon        CC                94                      51                      25.0                      1.00                    
                                          TC                41                      13                    25.4^C^               0.56 (0.30 1.05)       0.070      0.039
                                          TT                 5                       1                    24.0^c^               0.33 (0.04 2.41)       0.271      0.270
                                       TC + TT              46                      14                    25.7^c^               0.53 (0.29 0.97)       0.039      0.023
                rs2071336     Exon        CC                114                     56                      45.0                      1.00                    
                                          TC                24                       7                    26.3^C^               0.49 (0.22 1.09)       0.081      0.075
                                          TT                 3                       0                       NC                        NC               NC          NC
                                       TC + TT              27                       7                    26.8^C^               0.45 (0.21 1.00)       0.049      0.038

^a^The total number of individuals may not be the same because of genotyping failure. ^b^Adjusted for sex, subtype, and IPI score. ^c^Mean survival time is provided because median survival time is not reached.

The 5-year survival rates of patients carrying the rs3759333CC, TC, and TT genotypes were 51.7%, 43.0%, and 25.2%, respectively. The HR of death for patients carrying the TT genotype was 2.46 compared to patients with the CC genotype (95% CI: 1.22-4.97; *P* = 0.012). The 5-year survival rates of patients carrying the rs2017662CC, TC, and TT genotypes were 34.3%, 56.7%, and 66.7%, respectively. The HR of death for patients carrying the TT or TC genotype was 0.53 compared to those carrying the CC allele (95% CI: 0.29-0.97; *P* = 0.039). The 5-year survival rates of patients carrying the rs2071336CC and TC genotypes were 38.9% and 63.2%, respectively. The HR of death for patients carrying the TT or TC genotype was 0.45 compared to those carrying the CC allele (95% CI: 0.21-1.00; *P* = 0.049). [Figure 1](#cjc-31-07-335-g001){ref-type="fig"} shows Kaplan-Meier survival curves of all patients.

![Kaplan-Meier estimates of overall survival of the patients with T-cell lymphoma according to LTβR rs3759333 (A), TNFRSF17 rs2017662(B), and TNFRSF17 rs2071336 (C) genotypes. All *P* values are for log-rank tests.](cjc-31-07-335-g001){#cjc-31-07-335-g001}

Discussion {#s4}
==========

In this study, we investigated the association bewteen SNPs in *TNFRSF* genes and prognosis of TCL. The binding of TNF to TNFR can induce two opposite signaling pathways: one activates cell death process through the combination of TNFR I and FAS-associated death domain (FADD), leading to cell apoptosis; the other activates nuclear factor-kappa B (NF-kB) and c-Jun N-terminal kinase (JNK) through the combination of TNFR and TNFR-associated factors (TRAF), promoting cell survival and proliferation. Hence, the complex biological effects induced by the binding of TNF to TNFR play significant roles in cell fate. It has been shown that TNFR family members are involved in the development and progression of malignant tumors and play an important role in cell apoptosis and inflammatory reactions[@b8],[@b9]. Previous studies have reported that SNPs in the *TNF* and *TNFRSF* genes are associated with susceptibility to human cancers, including NHL[@b10]--[@b12]. Wang *et al.*[@b6] systematically examined the relationship between 500 tag SNPs in *TNF* and *TNFRSF* genes and susceptibility to NHL and noted that the SNP in 6p21.3 region was related with patient survival.

This study systematically analyzed the association between tag SNPs in 18 *TNFRSF* genes and the survival of patients with TCL. Our results indicated that three SNPs in the *LTβR* and *TNFRSF17* genes were associated with the survival of TCL patients. *LTβR* plays an essential role in the genesis of secondary lymph tissues and T cells and can activate the NF-kB pathway and induce cellular physiologic changes[@b13]--[@b16]. *TNFRSF17*, mainly expressed in mature B cells, plays a vital role in B-cell development and immune response[@b17]. *TNFRSF17* can directly combine with cytokine BAFF (also known as B-cell activating factor) to activate the NF-kB and MAPK/JNK pathways. Moreover, *TNFRSF17* can combine with TRAF family members to induce cell apoptosis and proliferation[@b18]. Other studies have also shown that *TNFRSF17* can promote cell apoptosis by T-cell dependent activation of memory B cells[@b19].

rs3759333 located at *LTβR* might affect the binding of transcriptional factors to DNA, influencing *LTβR* transcription, thereby resulting in the differentiation of unconventional T cells expressing the γδT-cell receptor. Such unconventional T cells play a vital role in regulating host immune responses, including resisting viral infection and cancer cell invasion[@b13]. Both rs2017662 and rs2071336 located in the coding region of *TNFRSF17* are synonymous mutations. Synonymous mutation may also affect gene function via a variety of mechanisms. For example, synonymous mutation may create microRNA-binding sites to facilitate mRNA degradation and influence the efficiency of protein translation, eventually affecting the expression of gene products. However, more studies need to be done to elucidate the exact biological mechanism underlying the relationship between genetic variations and the survival of TCL patients.

In summary, we found 3 SNPs in 18 *TNFRSF* genes associated with the survival of patients with TCL. Our results might have potential application in clinical care of TCL patients. However, further studies with large sample size are needed to confirm our results.
